Compumedics (ASX:CMP) granted U.S. FDA for Neuroimaging technology
- Compumedics (CMP) has received clearance from the U.S. Food and Drug Administration (FDA) for its neuroimaging technology
- The clearance allows for routine clinical use of the MEG devices, mainly for epilepsy and pre-surgical brain function mapping
- Sites using the technology can now routinely bill private and public insurance plans for the examination
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $57.66M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 30.0¢ | $21.73K | 72.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 6092 | 1 |
View Market Depth
| Last trade - 14.52pm 13/08/2025 (20 minute delay) ? |
| CMP (ASX) Chart |